Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback

GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it put more pressure on the company to deliver on its respiratory launches.